Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PRESS RELEASE Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate Synthetic vaccine designed to prime T-Cells to rapidly remove...
-
PRESS RELEASE Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate Synthetic vaccine designed to prime T-Cells to rapidly remove...
-
PRESS RELEASE Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine Swiss regulatory authorities, including the Swiss Agency for Therapeutic...
-
PRESS RELEASE Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells First detailed, empirical analysis of Class 1 epitopes presented by...
-
PRESS RELEASE Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells First detailed, empirical analysis of Class 1 epitopes presented by...